Eisai and Biogen present new five-year lecanemab data at CTAD 2026

16/11/2026

Eisai and Biogen have announced new five-year data from the Clarity AD long-term extension (LTE) study, showing that the benefits of continuous treatment with lecanemab in people with early Alzheimer’s disease (AD) continue to accrue over time. The findings were presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, US. 
Clarity AD is a global Phase III, randomised, double-blind, placebo-controlled and parallel-group study involving 1,795 participants with early AD. Following completion of the 18-month core study, 95% of participants chose to continue in the LTE study, in which all participants received lecanemab. A total of 351 participants received five years of continuous treatment.
The findings showed that continuous lecanemab treatment reduced the relative risk of progression to the next stage of AD by 36% compared with disease progression observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a long-running US research project following older adults with and without cognitive impairment. By year five, 61.9% of continuously treated participants progressed from mild cognitive impairment (MCI) to mild AD dementia or from mild AD dementia to moderate dementia by five years, compared with 77.5% in the ADNI data.
Similar results were also observed among participants with lower levels of tau accumulation in the brain. In an optional tau PET substudy, 66% of patients in the low-tau subgroup showed no decline (remaining stable or improving) on the CDR-SB after five years of treatment, while 62% showed improvement.
No new safety findings were observed during five years of continuous lecanemab treatment. Amyloid-related imaging abnormalities with oedema/effusion (ARIA-E) occurred most frequently within the first six months of treatment.
The companies said the findings suggest that initiating and continuing lecanemab treatment in the earlier stages of early AD may help slow clinical decline and provide sustained long-term benefit.
https://investors.biogen.com/news-releases/news-release-details/new-five-year-lecanemab-data-clarity-ad-study-long-term